RE:RE:RE:RE:Don’t expect a halt.I think the math works but I think 20m tests is too conservative, assuming they can get capacity which I think they will, as a simple cassette test cant be that hard to retool a pregnancy test line for example.
However even though I suspect we will have more covid in the future I dont think you can apply a multiple to what is basically one time revenue. However that still has huge upside. Even at 20m with your math we have 5.83 per share PROFIT. Then add whatever you think the company with the now proven technology and exposure is worth. Easy 10+ IMO.